Pharmaceutical industry

Mylan Underpaid U.S. on Rebates for EpiPen
Risk & Compliance

Mylan Underpaid U.S. on Rebates for EpiPen

A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
By Matthew Heller | October 6, 2016
Read More
Merck Buys Cough Drug Developer for $1.25B
Strategy

Merck Buys Cough Drug Developer for $1.25B

The acquisition of Afferent Pharmaceuticals gives Merck access to a drug candidate for treating neurogenic conditions including chronic cough.
By Katie Kuehner-Hebert | June 10, 2016
Read More
Pfizer Adds Eczema Gel With $5B Anacor Deal
Strategy

Pfizer Adds Eczema Gel With $5B Anacor Deal

If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
By Katie Kuehner-Hebert | May 16, 2016
Read More
Biotech CFO Accused of Misleading Investors
Risk & Compliance

Biotech CFO Accused of Misleading Investors

The ex-CFO of Aveo Pharmaceuticals and other top executives allegedly failed to disclose FDA concerns about an experimental cancer drug.
By Matthew Heller | March 30, 2016
Read More
Ireland’s Shire Buys Baxalta for $32 Billion
Strategy

Ireland’s Shire Buys Baxalta for $32 Billion

The drug maker says the deal will further its goal of "building the leading biotechnology company focused on rare diseases."
By Katie Kuehner-Hebert | January 11, 2016
Read More
Valeant Stock Falls 10% on News of CEO’s Illness
People

Valeant Stock Falls 10% on News of CEO’s Illness

Michael Pearson, who was hospitalized with pneumonia, has been trying to win back investor trust amid concerns over Valeant's pricing practices.
By Katie Kuehner-Hebert | December 28, 2015
Read More
Novartis Settles Kickback Charges for $370M
Risk & Compliance

Novartis Settles Kickback Charges for $370M

The Swiss drug maker allegedly turned specialty pharmacies into a "biased sales force" for its medications.
By Matthew Heller | November 20, 2015
Read More
Shire to Buy Rival Drug Maker Dyax for $5.9B
Strategy

Shire to Buy Rival Drug Maker Dyax for $5.9B

The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
By Matthew Heller | November 2, 2015
Read More
Cipla Buys Two U.S. Pharma Firms for $550M
Strategy

Cipla Buys Two U.S. Pharma Firms for $550M

The acquisitions give the Indian drug maker its first manufacturing plant in the U.S. and an opportunity to build U.S. market share.
By Katie Kuehner-Hebert | September 4, 2015
Read More
Teva to Buy Allergan’s Generic Drug Unit for $40.5B
Strategy

Teva to Buy Allergan’s Generic Drug Unit for $40.5B

If the deal is approved, Teva says the combined company would have revenue of about $26 billion and EBITDA of $9.5 billion in 2016.
By Katie Kuehner-Hebert | July 27, 2015
Read More